Drupal.behaviors.print = function(context) {window.print();window.close();}>
DiagnoCure Q4 Revenues Slide 59 Percent, Terminates Deal with Signal Genetics
January 14, 2013
DiagnoCure Q4 Revenues Slide 59 Percent, Terminates Deal with Signal Genetics
By
a GenomeWeb staff reporter
Full-text access for registered users only.
Existing users
login here
.
New to GenomeWeb?
Register here
quickly for free access.
Related Stories
DiagnoCure Posts Sharp Q3 Revenue Increase; Warns It May Not Receive Payment for Services Rendered
September 6, 2012 / GenomeWeb Daily News
FDA Approves Gen-Probe's Assay for Prostate Cancer
February 15, 2012 / GenomeWeb Daily News
Gen-Probe to File PMA for PCA3 Assay; Possible Alternative to PSA
September 2, 2009 / Pharmacogenomics Reporter
Gen-Probe Acquisition Drives up Hologic's Q2 Revenues 30 Percent
May 6, 2013 / GenomeWeb Daily News
Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider